Section
A prospective registry study found a U-shaped relationship between respiratory drive/effort and ICU outcomes: both low and high drive/effort linked with higher mortality and slower discharge, especially when oxygenation (PaO2:FiO2) ≤150 mmH
NEJ045A shows durvalumab plus carboplatin–etoposide is feasible in ES‑SCLC patients with PS2–3, with induction completion rates above thresholds and a 1‑year survival of 43.4% overall, supporting cautious use of chemo‑immunotherapy in selec
Three complementary studies—EVEREST (head‑to‑head RCT), the US ADVANTAGE real‑world study, and a target‑trial emulation—consistently show greater reductions in nasal polyp burden, smell loss, asthma exacerbations, and systemic steroid use w
Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurr
In HANSE, PLCOm2012 (6‑year risk ≥1.58%) selected more lung cancers and yielded a lower number needed to screen than NELSON criteria, supporting risk-model selection for CT screening programs, with caveats on generalisability and mortality
A JAMA serial cross‑sectional analysis finds US outpatient inhaler dispensing (2014–2024) produced ~24.9 million metric tons CO2e, mostly from metered‑dose inhalers; policy and clinical shifts to dry‑powder/soft‑mist devices and low‑GWP pro
A UK multicentre randomized placebo‑controlled trial (MABEL) showed no improvement in worst breathlessness with low‑dose oral morphine versus placebo at 28 days, with more adverse events and withdrawals in the morphine arm.
In a multicentre test‑negative study of 1006 adults aged 75–79 in England, a bivalent RSV pre‑F vaccine reduced RSV‑associated hospitalisation by 82% overall and protected against severe disease and exacerbations of chronic heart and lung d
A randomized trial in India found no superiority of oral voriconazole over itraconazole for chronic pulmonary aspergillosis at 6 months; efficacy was similar, but voriconazole caused more adverse events.
The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse even
A concise guide to the newly published Core Outcome Set for Post COVID-19 Condition (COS‑PCC): the nine prioritized outcomes, recommended measurement instruments, timing considerations, and implications for research and care.
A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlig
This comprehensive review synthesizes recent evidence on brand-specific influenza vaccine effectiveness (VE) among adults aged ≥65 in Denmark, Finland, and Sweden during the 2024-2025 season, underscoring heterogeneous VE profiles and the c
A quality improvement program significantly increased obstructive sleep apnea testing in stroke and TIA patients, advancing guideline-based care in cerebrovascular health.
A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.
In patients extubated after ≥7 days of mechanical ventilation, 43% had persistent inspiratory muscle weakness at hospital discharge. Maximal inspiratory pressure (MIP) measured 12 days after diagnosis strongly predicted persistent weakness
A systematic review and meta-analysis found no clear mortality, oxygenation, or safety benefit for prolonged prone positioning (≥24 h) in ARDS; evidence is low to very low certainty and does not support routine use outside clinical trials.
In a prespecified secondary analysis of the DAN‑RSV randomized trial, the bivalent RSV prefusion F vaccine showed comparable effectiveness against RSV‑related respiratory hospitalizations in adults ≥60 years with and without pre‑existing at
A multicenter test-negative case-control study in France found high and sustained effectiveness of nirsevimab against RSV bronchiolitis in infants across two consecutive seasons (83.2% and 89.3%), despite emergence of RSV-B mutations.
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
